A Safety Assessment of Fixed Combinations of Acetaminophen and Acetylsalicylic Acid, Coformulated with Caffeine

References

• Adams DH, Howie AJ, Michael J, McConkey B, Bacon PA, Abu D. Nonstanidal anti-inflammatory drugs and renal failure. Lancet 1986; 1: 57–59
   PubMed Web of Science ®Google Scholar
• Bach PH, Bridges JW. Chemically induced renal papillary necrosis and upper urothelial carcinoma. CRC Crit Rev Toxicol 1985; 15: 217–439
   Web of Science ®Google Scholar
• Eknoyan G. Current status of chronic analgesic and nonsteroidal anti-inflammatory drug nephropathy. Curr Opin Nephrol Hypertens 1994; 3: 182–188
   PubMedGoogle Scholar
• Kincaid-Smith P. Analgesic Nephropathy. Aust NZ J Med 1988; 18: 251–255
   PubMedGoogle Scholar
• Murray TG, Goldberg M. Analgesic abuse and renal disease. Ann Rev Med 1975; 26: 537–550
   PubMed Web of Science ®Google Scholar
• Murray TG, Goldberg M. Analgesic associated nephropathy in the USA: Epidemiologic Clinical and Pathogenic Features. Kidney Int 1978; 13: 64–71
   PubMed Web of Science ®Google Scholar
• Buckalew VM, Jr, Schey HM. Renal disease from habitual antipyretic analgesic consurnption: an assessment of the cpidmniologic evidence. Medicine 1986; 65: 291–303
   PubMed Web of Science ®Google Scholar
• Gonwa TA, Hamilton RW., Buckalew VM. Chronic renal failure and end-stage renal disease in northwest North Carolina. Importance of an algesio-associated nephropathy. Arch Intern Med 1981; 141: 462–465
   PubMedGoogle Scholar
• Maher JF. Analgesic nephropathy. Observations interpretations and perspective on the low incidence in America. Am J Med 1984; 76: 345–348
   PubMed Web of Science ®Google Scholar
• Wing AJ, Brunner FP, Geerling W. Contribution of toxic nephropathies to end-stage renal failure in Europe: a repot from the EDTA-ERA registry. Tox Lett 1989; 46: 281–292
   PubMed Web of Science ®Google Scholar
• Elseviers MM, Bosteels V, Cambier P, de Paepe M, Godon JP, Lins R, Lomoy W, Matthys E, Moeremans C, Roose R. Diagnostic errteria of analgesic nephropathy in patients with and-stage renal failure: Results of the Belgian study. Nephrol Dial Transplant 1992; 7: 479–486
   PubMed Web of Science ®Google Scholar
• Elseviers MM, de Schepper A, Corthouts R, Bosmans J-L, Cosyn L, Lins RL, Lomoy W, Matthys E, Roose R., Van Caesbrook D, Waller I, Horackova M., Schwarz A, Svroek P, Bonucchi D, Franek E, Morlans M, de Broe ME. High diagnostic performance of CT scan for analgesic nephropathy in patients with incipient to severe renal failure. Kidney Int 1995; 48: 1316–1323
   PubMed Web of Science ®Google Scholar
• Elsevier MM, Waller I, Nenoy D, Levora J, Matousovic K, Tanquerel T, Pommer W, Schwarz A, Keller E, Thieler H. Evaluation of diagnostic criteria for analgesic nephropathy in patients with end-stage renal failure: results of the ANNE study. Analgesic Nephropathy Network of Europe. Nephrol Dial Transplant 1995; 10: 808–814
   PubMed Web of Science ®Google Scholar
• Bennett WM, DeBroe ME. Analgesic Nephropathy—a preventable renal disease. N Engl J Med 1989; 320: 1269–1271
   PubMed Web of Science ®Google Scholar
• Elseviers MM, de Broe ME. Is analgesic nephropathy still a problem in Belgium?. Nephr Dial Transpl 1988; 2: 143–149
   Google Scholar
• de Broe ME, Elseviers MM. Analgesic nephropathy-still a problem?. Nephron 1993; 64: 505–513
   PubMed Web of Science ®Google Scholar
• de Brae ME, Elseviers MM, Bengtsson U., Mihatsch MJ, Molzahn M, Pommer W, Ritz E, Schwarz A. Analgesic Nephropathy. Nephrol Dial Transplant 1996; 11: 2407–408
   PubMed Web of Science ®Google Scholar
• Drukker W, Schwarz A., Vanherweghem JL. Analgesic nephropathy: an underestimated cause of end-stage renal disease. Int J Artif Organs 1986; 9: 219–246
   PubMed Web of Science ®Google Scholar
• Duggin GG. Combination analgesic-induced kidney disease: the Australian experience. Am J Kidney Dis 1996; 28: S39–47
   PubMed Web of Science ®Google Scholar
• Henrich WL. Analgesic nephropathy. Am J Med Sci 1988; 295: 561–568
   PubMed Web of Science ®Google Scholar
• Schwarz A. Analgesic-associated nephropathy. Klin Wochenschr 1987; 65: 1–16
   PubMedGoogle Scholar
• Henrich WL., Agodoa LE, Barrett B, Bennet WM, Blantz RC, Buckalew VM, D'Agati VD, de Broe ME, Duggin GG, Eknoyan G. National Kidney Foundation Position Paper. Analgesics and the kidney. Am J Kidney Dis 1996; 27: 162–165
   PubMed Web of Science ®Google Scholar
• Levy M. Adverse reactions to over-the counter analgesics: an epidemiological evaluation. Agents Actions 1988; 25: 21–31, Suppl
   PubMedGoogle Scholar
• Whelton A. Renal effects of over-the-counter analgesics. J Clin Pharmacol 1995; 5: 454–463
   Google Scholar
• Fox JM and members of the German Federal Drug Evaluation Committee. Kombinationsarzneimittel aus Paracetamol plus Acetylsalicylsäure—Nurses und Risiken (Combination drugs of paracetamol and acetylsalicylic acid—Benefit and Risks). Der Schmerz 1995; 9: 273–285
   PubMed Web of Science ®Google Scholar
• Bundesgesundheitsamt. Monogaphie: Acetylsalicylsäure plus Paracetamol in fixer Kombination. Bundesanzeiger 46. No. 1994; 88: 4975–4978
   Google Scholar
• Sawynok J, Yaksh TL. Caffeine as an analgesic adjuvant: a review of pharmacology and mechanisms of action. Pharmacol Rev 1993; 45: 43–85
   PubMed Web of Science ®Google Scholar
• Schadrtel BP, Fillingim JM, Lane AC, Thoden WR, Baybutt RI. Caffeine as an analgesic adjuvant. A double-blind study comparing aspirin with caffeine to aspirin and placebo in patients with sore throat. Arch Intern Med 1991; 151: 733–737
   PubMedGoogle Scholar
• Koch GG, Amara IA, MacMillan J. Evaluation of alternative statistical models for crossover studies to demonstrate caffeine adjuvancy in the treatment oftension headache. J Biopharm Stat 1994; 4: 347–410
   PubMedGoogle Scholar
• Migliardi JR, Amnellino JJ, Friedman, Gillings DB, Beaver WT. Caffeine as an analgesic adjuvant in tension headache. Clin Pharmacol Ther 1994; 56: 576–586
   PubMed Web of Science ®Google Scholar
• Forbes JA, Beaver WT, Jones KF, Kehm CJ, Smith WK, Gongloff CM, Zeleznock JR, Smith JW. Effect of caffeine on ibuprofen analgesia in postoperative oral surgery pain. Clin Pharmacol Ther 1991; 49: 674–684
   PubMed Web of Science ®Google Scholar
• Sawynok J. Pharmacological rationale for the clinical use of caffeine. Drugs 1995; 49: 37–50
   PubMed Web of Science ®Google Scholar
• Thithapandha A. Effect of caffeine on the bioavailability and pharmacokinetics of aspirin. J Med Assoc Thai 1989; 72: 562–566
   PubMedGoogle Scholar
• Williams M, Jarvis MF. Adenosine antagonists as potential therapeutic agents. Pharmacol Biochem Behav 1988; 29: 433–441
   PubMed Web of Science ®Google Scholar
• Barnett BJ. Acetaminophen and adverse chronic renal outcomes: an appraisal of the epidemiologic evidence. Am J Kidney Dis 1996; 28: S14–19
   PubMed Web of Science ®Google Scholar
• Bennet WM, Henrich WL, Stoff JS. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Am J Kidney Dis 1996; 28: S56–62, Suppl 1
   Web of Science ®Google Scholar
• Elseviers MM, de Broe ME. Analgesic Nephropathy in Belgium is related to sales of particular analgesic mixtures. Nephrol Dial Transplant 1994; 9: 41–46
   PubMed Web of Science ®Google Scholar
• Elseviers MM, de Broe ME. Combination analgesic involvement in the pathogenesis of analgesic nephropathy: the European perspective. Am J Kidney Dis 1996; 28: S48–55
   Web of Science ®Google Scholar
• Delzell E, Shapiro S. Commentary co the National Kidney Foundation position paper on analgesics and the kidney. Am J Kidney Dis 1996; 28: 783–785
   PubMed Web of Science ®Google Scholar
• Delzell E, Shapiro S. A review of epidemiologic studies of nonnarcotic analgesics and chronic renal disease. Medicine 1998; 77: 102–21
   PubMed Web of Science ®Google Scholar
• Dubach UC, Rosner B, Levy PS, Baumeler HR, Muller A, Peyer A, Ehrensperger T, Ettlin C. Epidemiological study in Switzerland. Kidney Int 1978; 13: 41–49
   PubMed Web of Science ®Google Scholar
• Dubach UC. Analgesic nephropathy. Epidemiological studies and pharmacological investigations. Contrib Nephrol 1979; 16: 65–69
   PubMedGoogle Scholar
• Dubach UC, Rosner B, Sturmer T. An epidemiologic study of abuse of analgesic drugs. Effects of phenacetin and salicylate on mortality and cardiovascular morbidity: 1968 to 1987. N Engl J Med 1991; 324: 155–160
   PubMed Web of Science ®Google Scholar
• Dubach UC, Rosner B, Sturmer T. Epidemiologic study of analgesic abuse: mortality study in 7275 working women: 1968–1987. Kidney Int 1991; 40: 728–733
   PubMed Web of Science ®Google Scholar
• Morlans M, Laporte JR, Vidal X, Cabeza D, Stolley PD. End-stage renal disease and non-narcotic analgesics: a case-control study. Br J Clin Pharmacol 1990; 30: 17–23
   Web of Science ®Google Scholar
• Sandler DP, Smith JC, Weinberg CR, Buckalew VM, Jr, Dennis VW, Blythe WB, Burgess WP. Analgesic use and chronic renal disease. N Engl J Med 1989; 320: 1238–1243
   PubMed Web of Science ®Google Scholar
• Pormner W, Bronder E, Greiser E, Helmert U, Jesdinsky HJ, Klimpel A, Bomer K, Molzahn M. Regular analgesic intake and the risk of end-stage renal failure. Am J Nephrol 1989; 9: 403–412
   PubMed Web of Science ®Google Scholar
• McCredie M, Stewart JH, Mahony JF. is phenacetin responsible for analgesic nephropathy in New South Wales?. Clin Nephrol 1982; 17: 134–140
   PubMed Web of Science ®Google Scholar
• Steenland NK, Thun MJ, Ferguson CW, Port FK. Occupational and other exposures associated with male end stage renal disease: a case/control study. Am J Public Health 1990; 80: 153–157
   PubMed Web of Science ®Google Scholar
• Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen aspirin and nonsteroidal antiinflammatory drugs. N Engl J Med 1994; 331: 1675–1679
   PubMed Web of Science ®Google Scholar
• Sandler DP, Burr FR, Weinberg CR. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med 1991; 115: 165–172
   PubMed Web of Science ®Google Scholar
• Fox JM. No proof for a particular role of combination analgesics causing end-stage renal failure. [letter]. Nephrol Dial Transplant 1996; 11: 2519–2520
   PubMed Web of Science ®Google Scholar
• Noels LM, Elseviers MM, de Broe ME. Impact of legislative measures on the sales of analgesics and the subsequent prevalence of analgesic nephropathy: a comparative study in France Sweden and Belgium. Nephrol Dial Transplant 1995; 10: 167–174
   PubMed Web of Science ®Google Scholar
• Abbot PJ. Caffeine: a toxicological overview. Med J Aust 1986; 145: 518–520
   PubMed Web of Science ®Google Scholar
• Kalow W. Caffeine and ether drugs. Prog Clin Biol Res 1986; 214: 331–341
   PubMedGoogle Scholar
• Benowitz NL. Clinical pharmacology of caffeine. Annu Rev Med 1990; 41: 277–288
   PubMed Web of Science ®Google Scholar
• Boyd EM, Dolman M, Knight LM, Sheppard EP. The chronic oral toxicity of caffeine. Can J Physiol Pharmacol 1965; 43: 995–1007
   Web of Science ®Google Scholar
• Boyd EM. The acute oral toxicity of caffeine. Tox Appl Pharmacol 1959; 1: 250–257
   PubMed Web of Science ®Google Scholar
• Dalvi RR. Acute and chronic toxicity of caffeine: a review. Vet Hum Toxicol 1986; 28: 144–150
   PubMedGoogle Scholar
• Somani SM, Gupta P. Caffeine: a new look at an age-old drug. Int J Clin Pharmacol Ther Toxicol 1988; 26: 521–33
   PubMed Web of Science ®Google Scholar
• Goldstein A, Kaizer S, Whitby O. Psychotropic effects of caffeine in man. IV. Quantitative and qualitative differences associated with habituation to coffee. Clin Pharmacol Ther 1969; 10: 489–497
   PubMed Web of Science ®Google Scholar
• Lieberman HR, Wurtman RJ, Emde GG, Coviella IL. The effects of caffeine and aspirin on mood and performance. J Clin Psychopharmacol 1987; 7: 315–320
   PubMed Web of Science ®Google Scholar
• Pickworth WB. Caffeine dependence. Lancet 1995; 345: 1066
   PubMed Web of Science ®Google Scholar
• Stephenson PE. Physiologic and psychotropic effects of caffeine on man. A review. J Am Diet Assoc 1977; 71: 240–247
   PubMedGoogle Scholar
• Hughes JR, Oliveto AH., Helzer JE, Higgins ST, Bickel WK. Should caffeine abuse dependence or withdrawal be added to DSM-IV and ICS 10?. Am J Psychiatry 1992; 149: 33–40
   PubMed Web of Science ®Google Scholar
• Fox JM and members of the German Federal Evaluation Committee. Coffein plus Analgetika—eine sinnvolle Kombination (Caffeine plus analgesics—a meaningful combination). Der Schmerz 1988; 2: 183–197
   PubMedGoogle Scholar
• Bundesgesundheitsant. Monographie: Paracetamol plus Coffein in fixer Kombination. Bundesanzeiger 41. No. 1988; 209: 4778–4779
   Google Scholar
• Bundesgesundheitsamt. Monographic: Acetylsalicylsäure plus Coffein in fixer Kombination. Bundesanzeiger 46. No. 1994; 31: 1247–1249
   Google Scholar
• Greden JF, Victor BS, Fontaine P, Lubasky M. Caffeine-withdrawal headache: a clinical profile. Psychosomatics 1980; 21: 411–413; 417–418
   PubMed Web of Science ®Google Scholar
• Smith R. Caffeine withdrawal headache. J Clin Pharm Ther 1987; 12: 53–57
   PubMed Web of Science ®Google Scholar
• Shorofsky MA, Lamm RN. Caffeine-withdrawal headache and fasting. N Y State J Med 1977; 77: 217–218
   PubMedGoogle Scholar
• Rainey JT. Headache related to chronic caffeine addiction. Tex Dent. J 1985; 102: 29–30
   PubMedGoogle Scholar
• Murray RM. Genesis of analgesic nephropathy in the United Kingdom. Kidney Int 1978; 13: 50–57
   PubMed Web of Science ®Google Scholar
• Hobi V, Ladewig D, Dubadh UC, Miest P-Ch, Ehrensberger T. Analgesic abuse and personality characteristics. Int J Clin Pharmacol Biopharm 1976; 13: 36–41
   PubMedGoogle Scholar
• Murray RM. Personality factors in analgesic nephropathy. Psychol Med 1974; 4: 69–73
   PubMed Web of Science ®Google Scholar
• Ladewig D, Miest PC, Dubach UC, Ettlin C, Hobi V. Use and abuse of non-narcotic analgesics. Drug Alcohol Depend 1978; 3: 435–442
   PubMed Web of Science ®Google Scholar
• Appel RG, Bleyer AJ, McCabe JC. Case report: analgesic nephropathy: a soda and a powder. Am J Med Sci 1995; 310: 161–166
   PubMed Web of Science ®Google Scholar
• Michielsen P, de Schepper P. Analgesic nephropathy in Belgium: Contusion between prevalence and incidence. Am J Kidney Dis 1996; 28: 958–959
   PubMed Web of Science ®Google Scholar
• Michielsen P, de Schepper P. Combination analgesic involvement in the pathogenesis of analgesic nephropathy. Am J Kidney Dis 1996; 28: 959–960
   PubMed Web of Science ®Google Scholar
• Wilson DR, Gault MU. Declining incidence of analgesic nephropathy in Canada. Can Med Assoc J 1982; 127: 500–502
   PubMed Web of Science ®Google Scholar
• Stewart JH, Mc Credie M, Disney APS, Mathew TH. Trends in incidence of end-stage renal failure in Australia: 1972–1991. Nephrol Dial Transplant 1994; 9: 1377–382
   PubMed Web of Science ®Google Scholar
• Brunner FP, Selwood NH. End-stage renal failure due to analgesic nephropathy its changing pattern and cardiovascular mortality. EDTA-ERA Registry Committee. Nephrol Dial Transplant 1994; 9: 1371–1376
   PubMed Web of Science ®Google Scholar
• Segasothy M, Tong BK, Kamal A., Murad Z., Suleiman AB. Analgesic nephropathy associated with paracetamol. Aust N Z J Med 1984; 14: 23–26
   PubMedGoogle Scholar
• Segasothy M, Suleiman All, Puvaneswary M., Rohana A. Paracetamol: a cause ter analgesic nephropathy and end-stage renal disease. Nephron 1988; 50: 50–54
   PubMed Web of Science ®Google Scholar
• Segasothy M, Samad SA, Zulfigar A, Bennett WM. Chronic renal disease and papillary necrosis associated with the long-term use of nonsteroidal anti-inflammatory drugs as the sole or predominant analgesic. Am J Kidney Dis 1994; 24: 17–24
   PubMed Web of Science ®Google Scholar
• Segasothy M, Thyaparan A, Kamal A, Sivalingam S. Mefenamic acid nephropathy. Nephron 1987; 45: 156–157
   PubMed Web of Science ®Google Scholar
• Segasothy M, Chin GL, Sia KK., Zulfigar A, Samad SA. Chronic nephrotoxicity of anti-inflammatory drugs used in the treatment of arthritis. Br J Rheumatol 1995; 34: 162–165
   PubMedGoogle Scholar
• Caruana RJ, Semble EL. Renal papillary necrosis due to naproxen. J Rheumatol 1984; 11: 90–91
   PubMed Web of Science ®Google Scholar
• Prescott LF. Kinetics and metabolism of paracetamol and phenacetin. Br J Clin Pharmacol 1980; 10: 291S–298S, Suppl 2
   PubMed Web of Science ®Google Scholar
• Joshi S, Zaiser TV, Mattammal MB, Herman CA, Davis BB. Kidney metabolism of acetaminophen and phenacetin. J Lab Clin Med 1978; 92: 924–931
   PubMed Web of Science ®Google Scholar
• Hinson JA. Reactive metabolites of phenauetin and acetaminophen: a review. Environ Health Perspect 1983; 49: 71–79
   PubMed Web of Science ®Google Scholar
• Baumeler HR, Ettlin C, Dubach UC., Ladewig D. [Trends in urinary analgesic excretion in a cohort observed from 1968 to 1975]. Soc Praventivmed 1975; 20: 242–243
   PubMedGoogle Scholar
• Burrell JH, Yong JL, MacDonald GJ. Irreversible damage to the medullary interstitium in experimental analgesic nephropathy in F344 rats. J Pathol 1991; 164: 329–338
   PubMed Web of Science ®Google Scholar
• Burrell JH, Yang JL., MacDonald GJ. Analgesic nephropathy in Fischer 344 rats: comparative effects of chronic treatment with either aspirin or paracetamol. Pathology 1991; 23: 107–114
   PubMed Web of Science ®Google Scholar
• Black HE. Renal toxicity of non-steroidal anti-inflammatory drugs. Toxicol Pathol 1986; 14: 83–90
   PubMedGoogle Scholar
• Bach PH, Thanh NTK. Renal papillary necrosis—40 years on. Toxicol Pathol 1998; 26: 69–87
   Web of Science ®Google Scholar
• Bach PH, Bridges JW. The role of prostaglandin synthase mediated metabolic activation of analgesics and non-steroidal anti-inflammatory drugs in the development of renal papillary necrosis and upper urothelial carcinoma. Prostagland Leuk Med 1984; 15: 251–274
   PubMedGoogle Scholar
• Lehmann H, Hirsch U, Bauer F., Bauer M, Greischel A, Schmid J, Schneider P. Studies on the chronic oral toxicity of an analgesic drug combination consisting of acetylsalicylic acid paracetamol and caffeine in rats including an electron microscopical evaluation of kidneys. Arzneimittelforschung 1996; 46: 895–905
   PubMed Web of Science ®Google Scholar
• Macklin AW, Szot RJ. Eighteen month oral study of aspirin phenacetin and caffeine in C57BL/6 mice. Drug Chem Toxicol 1980; 3: 135–163
   PubMed Web of Science ®Google Scholar
• Mineshita S, Toyoshima A, Yazaki T. Influence of phehacetan and its metabolites on renal function. Nippon Jinzo Gakkai Shi 1989; 31: 629–633
   PubMedGoogle Scholar
• Champion-De-Crespigny P, Hewitson T, Birchall L, Kincaid-Smith P. Caffeine potentiates the nephrotoxicity of mefenamic acid on the rat renal papilla. Am J Nephrol 1990; 10: 311–315
   PubMed Web of Science ®Google Scholar
• Hewitson TD, Champion de Crespigny PJ, Kincaid-Smith P. Caffeine potentiation of mefenamic add-induced lesions in the rat renal medulla. J Pathol 1991; 165: 343–347
   PubMed Web of Science ®Google Scholar
• Murray MD, Brater DC. Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annu Rev Pharmacol Toxicol 1993; 33: 435–65
   PubMed Web of Science ®Google Scholar
• Carlton WW, Engelhardt JA. Experimental renal papillary necrosis in the Syrian hamster. Food Chem Toxicol 1989; 27: 331–340
   PubMed Web of Science ®Google Scholar
• Duggin GG. Mechanisms in the development of analgesic nephropathy. Kidney Int 1980; 18: 553–561
   PubMed Web of Science ®Google Scholar
• Davis BB., Mattammal MB, Zenser TV. Renal metabolism of drug and xenobiotics. Nephron 1981; 27: 187–196
   PubMed Web of Science ®Google Scholar
• Smith BJ., Curtis JF., Eling TE. Bioaotivation of xenobiotics by prostaglandin H synthase. Chem Biol Interact 1991; 79: 245–264
   PubMed Web of Science ®Google Scholar
• Mohandas J, Duggin GG, Horvath JS, Tiller DJ. Regional differences in peroxidatic activation of paracetamol (acetaminophen)-mediated by cytodttome P-450 and prostaglandin endoperoxide synthetase in rabbit kidney. Res Commun Chem Pathol Pharmacol 1981; 34: 69–80
   PubMedGoogle Scholar
• Mohandas J, Duggin GG, Horvath JS, Tiller DJ. Metabolic oxidation of acetaminophen (paracetamol)-mediated by cytochrome P-450 mixed function oxidase and prostaglandin endoperoxide synthetase in rabbit kidney. Toxicol Appl Pharmacol 1981; 61: 252–259
   PubMed Web of Science ®Google Scholar
• Ross D, Larsson R, Anderson B, Nilsson U, Lindquist T, Lindeke B, Moldeus P. The oxidation of p-phenetidine by horse radish peroxidase and prostaglandin synthase and the fate of glutathione during such oxidation. Biochem Pharmacol 1985; 34: 343–351
   PubMed Web of Science ®Google Scholar
• Nelson SD, Dahlin DC, Rauckman RJ, Rosen GM. Peroxidase-mediated formation of reactive metabolites of acetaminophen. Mol Pharmacol 1981; 20: 195–199
   PubMed Web of Science ®Google Scholar
• Mohandas J, Marshall JJ, Duggin GG, Horvath JS, Tiller DJ. Differential distribution of glutathione and glutathione-related enzymes in rabbit kidney. Biochem Pharmacol 1984; 33: 1801
   PubMed Web of Science ®Google Scholar
• Boyd JA, Eling TE. Prostaglandin endoperoxide synthetase-dependent cooxidation of acetaminophen to intermediates which covalently bind in vitro to rabbit renal medullary microsomes. J Pharmacol Exp Ther 1981; 219: 659–664
   PubMed Web of Science ®Google Scholar